Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Position Lowered by Laird Norton Wetherby Wealth Management LLC

Laird Norton Wetherby Wealth Management LLC lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,277 shares of the medical research company's stock after selling 840 shares during the period. Laird Norton Wetherby Wealth Management LLC's holdings in Thermo Fisher Scientific were worth $4,306,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of TMO. Cypress Advisory Group LLC acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $253,000. S.E.E.D. Planning Group LLC boosted its stake in Thermo Fisher Scientific by 6.2% during the 4th quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company's stock valued at $5,528,000 after acquiring an additional 618 shares during the last quarter. Czech National Bank increased its position in shares of Thermo Fisher Scientific by 6.6% in the 4th quarter. Czech National Bank now owns 82,934 shares of the medical research company's stock worth $43,145,000 after purchasing an additional 5,118 shares during the last quarter. Granite Bay Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $4,758,000. Finally, Courier Capital LLC grew its stake in Thermo Fisher Scientific by 148.8% in the fourth quarter. Courier Capital LLC now owns 20,914 shares of the medical research company's stock worth $10,880,000 after purchasing an additional 12,509 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. The trade was a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now owns 23,167 shares of the company's stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The disclosure for this sale can be found here. Insiders sold 14,075 shares of company stock valued at $7,305,942 over the last 90 days. 0.33% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts have issued reports on the company. Royal Bank of Canada cut their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Robert W. Baird reduced their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. StockNews.com lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Citigroup decreased their price target on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Finally, Wells Fargo & Company dropped their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. Five investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $607.43.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO traded down $1.78 on Thursday, hitting $404.27. The company's stock had a trading volume of 4,128,328 shares, compared to its average volume of 1,832,230. The company has a market capitalization of $152.61 billion, a price-to-earnings ratio of 24.46, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific Inc. has a 12 month low of $390.56 and a 12 month high of $627.88. The stock's 50-day moving average is $458.36 and its two-hundred day moving average is $512.38.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Thermo Fisher Scientific's quarterly revenue was up .2% on a year-over-year basis. During the same quarter last year, the company earned $5.11 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were issued a $0.43 dividend. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date was Friday, March 14th. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. Thermo Fisher Scientific's dividend payout ratio is 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.